Abstract
Neurointerventional surgery offers the potential to deliver remarkable intravascular therapies for various neurovascular diseases and stroke. This approach, however, carries a risk of complications that need to be kept to a minimum. Thromboembolism is one of the most consequential complications of neurointerventional surgery in the treatment of intracranial aneurysms. Both antiplatelet and anticoagulant therapies have shown to reduce the risk of thromboembolism in this setting. In this paper, we review the role of antiplatelet therapy in the endovascular management of intracranial aneurysms. For unruptured aneurysms, the use of antiplatelet agents to pre-medicate patients before and during the procedure appears safe and effective in reducing the thrombotic risk. Abciximab has not been extensively studied, but seems to be safe as a salvage maneuver in the case of thrombus formation even in ruptured aneurysms (when the dome is relatively secure) with low rates of intraprocedure and procedure hemorrhagic complications. Further innovation and research are needed to further reduce thromboembolic risks of aneurysm coiling.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
